Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration
- 31 May 1992
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (6-7) , 1049-1051
- https://doi.org/10.1016/0959-8049(92)90453-9
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- New views on rejection mechanisms and their relevance to interleukin-2 as a treatment for renal cell cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2British Journal of Cancer, 1991
- Low-dose regimen of interleukin-2 for metastatic renal carcinomaThe Lancet, 1990
- Evaluation of the effect of continuous infusion recombinant interleukin-2 (bioleukin) on peripheral blood leucocytes of patients with terminal malignancyBritish Journal of Cancer, 1989
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Metastatic Renal Cancer Treated with Interleukin-2 and Lymphokine-Activated Killer CellsAnnals of Internal Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Prognostic Factors in Metastatic Renal CarcinomaJournal of Urology, 1986
- Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.The Journal of Immunology, 1985